Trial reportScientific reports2026
Efficacy of argatroban plus alteplase versus intravenous alteplase according to diabetes mellitus in acute ischemic stroke.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We conducted a post hoc analysis of the ARAIS (Argatroban Plus Recombinant Tissue-Type Plasminogen Activator for AIS) trial to investigate whether diabetes mellitus (DM) affects the efficacy of argatroban plus alteplase in patients with acute ischaemic stroke (AIS). Patients were categorized into DM and non-DM subgroups. In each subgroup, outcomes were compared between the argatroban plus alteplase group and the alteplase alone group. Additionally, the interaction between DM and treatment efficacy was assessed. The primary outcome was excellent functional outcome at 90 days, which was defined as a modified Rankin Scale score of 0-1. A total of 696 patients were included in this study. Regarding the primary outcome, the treatment effect was comparable between the argatroban plus alteplase group and the alteplase alone group both in the DM subgroup (58.4% versus 63.0%; adjusted risk difference, 1.1%; 95% CI, -13.8% to 16.1%; P = 0.88) and the non-DM subgroup (65.8% versus 65.3%; adjusted risk difference, 0.9%; 95% CI, -6.9% to 8.7%, P = 0.81). No significant interaction was observed between DM and treatment effect on the primary outcome (P = 0.93). Compared with alteplase alone, the efficacy of argatroban plus alteplase in achieving excellent functional outcomes at 90 days did not differ by DM status in patients with AIS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.